Bilateral Mediastinal Lymphadenectomy is Associated with Potential Survival Advantages in Patients with Solid-Dominant Stage I Non-Small-Cell Lung Cancer Who Underwent Anatomic Lung Resection
Weidong Wang,Gongming Wang,Hongxu Sheng,Yutong Hong,Dechang Zhao,Rusi Zhang,Zirui Huang,Longjun Yang,Jian Hu,Lanjun Zhang
DOI: https://doi.org/10.2139/ssrn.3987084
2021-01-01
SSRN Electronic Journal
Abstract:Background: The optimal lymphadenectomy approach for solid-dominant stage I non-small-cell lung cancer (NSCLC) is controversial. The present study aimed to compare the survival outcomes following lobectomy with different varieties of lymphadenectomy in patients with solid-dominant stage I NSCLC.Methods: Patients diagnosed with solid-dominant stage I NSCLC from 2008 to 2015 were included and grouped according to the mode of lymphadenectomy. Disease-free survival (DFS) and overall survival (OS) were compared, and univariate survival analysis was performed among groups. Cox analysis was used to identify independent prognostic factors. Nomograms for survival prediction based on lymphadenectomy mode were constructed and internally calibrated. Propensity score matching (PSM) was used to balance the potential confounders. After PSM, subgroup comparisons between bilateral mediastinal lymphadenectomy (BML), systematic nodal dissection (SND), lobe-specific lymph node dissection (LSND) and systematic nodal sampling (SNS) were conducted.Findings: In total, 983 patients were included. The 5-year OS rates were 98.2%, 86.9%, 86.4%, 82.8% (p=0.006), and the 5-year DFS rates were 87.1%, 76.4%, 69.5%, 70.9% (p=0.008) in the BML, SND, LSND and SNS groups, respectively. Compared with SNS, BML was independently associated with better OS and DFS. After PSM, patients who underwent BML showed better OS (HR, 0.358; 95% CI, 0.127-1.008; p=0.052) and DFS (HR, 0.563; 95% CI 0.295-1.074; p=0.081) than those who underwent SND, with marginal significance. Compared with L-SND and SNS, BML was associated with significantly improved OS (HR, 0.343; 95% CI 0.123-0.958; p=0.041 and HR, 0.250; 95% CI 0.088-0.709; p=0.009, respectively) and DFS (HR, 0.474; 95% CI 0.258-0.868; p=0.016 and HR, 0.467; 95% CI 0.232-0.938; p=0.032, respectively). Subgroup analyses demonstrated that for male patients and those whose tumors were larger or more advanced, BML was associated with significantly better OS and DFS than other types of lymphadenectomy.Interpretation: In patients with solid-dominant stage I NSCLC, BML might be associated with better survival and is recommended for these patients, especially those with large tumors.Funding Information: This study was supported by the grant from the National Key R&D Program of China (2016YFC0905400).Declaration of Interests: The authors declare no conflicts of interest in this work.Ethics Approval Statement: This study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center (B2018-011) and the Medical Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University (2013-255-1).